Bristol-myers Squibb Compnay

Pfizer Corporation

Bolt Biotherapeutics, Inc.

Karla Ann Henning

Alan J Korman

Haichun Huang

Guodong Chen

Richard Y Huang

Mohan Srinivasan

Nils Lonberg

Mark J Selby

Michelle Minhua Han

Changyu Wang

Indrani Chakraborty

Huiming Li

Aaron Paul Yamniuk

Bryan C Barnhart

Ming Lei

Susan Wong

Maria N Jure-Kunkel

Martin J Corbett

Jun Zhang

Ginger Chao Rakestraw

Brigitte Devaux

Peter Brams

Shrikant Deshpande

Tetsuya Ishino

Arvind Rajpal

Kent B Thudium

Han Chang

Mark F Maurer

Susan Chien-Szu Wong

Xi-Tao Wang

Brenda L Stevens

Jochem Gokemeijer

Alexander T Kozhich

Christine Bee

Thomas D Kempe

Michael Quigley

Sandra V Hatcher

Liang Schweizer

John S Sack

Angela Goodenough

Joseph E Myers, Jr

Emanuela Sega

Pingping Zhang

Vangipuram S Rangan

Xiang Shao

Natalie Bezman

Robert Arch

Joel Bard

Ciara Reilly

Orla Cunningham

William Finlay

Amy D Jhatakia

Shelley Erin Ackerman

Justin A Kenkel

Hadia Lemar

Olufemi A Adelakun

Anne C Lewin

David Dornan

Michelle M Mader

Zhehong Cai

Patrick Guirnalda

Christina Maria Milburn

Marie-Michelle Navarro Garcia

Joseph E Myers

Michelle Madar

Michelle Mader

Zheng Yang

Praveen Aanur

Christine Huang

Yan Feng

Ginger C Rakestraw

Maria Rodriguez

The present invention provides antibodies, or antigen-binding fragment thereof, which specifically bind to tumor necrosis factor (TNF)-like ligand (TL1A). The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of TL1A mediated diseases, disorders or conditions.

Tumor necrosis factor-like ligand 1A specific antibodies and compositions and uses thereof

The invention relates to dendritic cell-associated C-type lectin 2 (Dectin-2) binding agents, nucleic acids comprising the inventive binding agents, vectors and cells comprising the inventive nucleic acids, and compositions thereof. The invention also relates to methods of providing the inventive binding agents, methods for treating a disease, disorder, or condition in a mammal, and methods of stimulating an antigen presenting cell.

Anti-Dectin-2 antibodies and methods of using

The present disclosure provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies), or antigen-binding fragments thereof, that specifically bind to human natural killer cell inhibitory receptor group 2A (NKG2A) protein with high affinity and exhibit therapeutically desirable functional properties, such as for the treatment of, for example, cancer. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the anti-NKG2A antibodies of the invention are also provided. Nucleic acid molecules encoding the antibodies, expression vectors, host cells, and methods of treatment of, for example, cancer using the antibodies are further provided. Combination therapy, in which an anti-NKG2A antibody in the present disclosure is co-administered with at least one additional agent such as another antibody (e.g., anti-PD-1, anti-PD-L1, and/or anti-CTLA-4 antibodies), is also provided.

Methods of treating HLA-E-expressing cancers by administering antibodies which bind human natural killer cell inhibitory receptor group 2A (NKG2A)

Nucleic acid molecules encoding antibodies which bind natural killer cell inhibitory receptor group 2A protein (NKG2A)

Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.

Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof

Anti-Dectin-2 antibodies

The present invention provides antibodies, or antigen-binding fragment thereof, which specifically bind to tumor necrosis factor (TNF)-like ligandA(TLA) The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of TLA mediated diseases, disorders or conditions.

Provided herein are diagnostic antibodies that bind to glucocorticoid-induced tumor necrosis factor receptor (GITR). Such antibodies are useful for methods of detecting the expression of GITR in biological samples, for example, tumor tissue, and identifying a cancer patient likely to respond to anti-GITR immunotherapy or predicting whether a cancer patient will respond to anti-GITR immunotherapy.

Anti-GITR antibodies for cancer diagnostics

The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.

Antibodies against CD73 and uses thereof

Anti-human natural killer cell inhibitory receptor group 2A protein (NKG2A) antibodies

Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR)

Provided herein are heavy chain constant regions (referred to as 'modified heavy chain constant regions'), or functionally equivalent fragments thereof, that enhance biological properties of antibodies relative to the same antibodies in unmodified form. An exemplary modified heavy chain constant region includes an IgG2 hinge and three constant domains (i.e., CH1, CH2, and CH3 domains), wherein one or more of the constant region domains are of a non-IgG2 isotype (e.g., IgG1, IgG3 or IgG4). The heavy chain constant region may comprise wildtype human IgG domain sequences, or variants of these sequences. Also provided herein are methods for enhancing certain biological properties of antibodies that comprise a non-IgG2 hinge, such as internalization, agonism and antagonism, wherein the method comprises replacing the non-IgG2 hinge of the antibody with an IgG2 hinge.

Antibodies comprising modified heavy constant regions

Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.

Growing community of inventors

Milpitas, CA, United States of America

Karla Ann Henning